Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

摘要: Progressive multifocal leukoencephalopathy (PML) onset, caused by Polyomavirus JC (JCPyV) in patients affected immune-mediated diseases during biological treatment, raised concerns about the safety profile of these agents. Therefore, aims this study were JCPyV reactivation monitoring and noncoding control region (NCCR) viral protein 1 (VP1) analysis different treated with biologics. We performed JCPyV-specific quantitative PCR samples collected at moment recruitment (t0) every 4 months (t1, t2, t3, t4). Subsequently, rearrangements’ NCCR VP1 was carried out. Data analyzed using χ2 test. Results showed that t0 chronic inflammatory rheumatic presented a load urine significantly higher (p≤0.05) than multiple sclerosis (MS) Crohn’s disease (CD). It can also be observed significant association between viruria antibodies after year natalizumab (p=0.04) MS patients. Finally, presence an archetype-like sequence all samples, whereas rearranged Type IR found colon-rectal biopsies from 2 CD 16 infliximab. Furthermore, sequences isolated peripheral blood mononuclear cells (PBMCs) antibody IIR duplication 98 bp unit 66 insert, resulting boxB deletion 37 T to G transversion into Spi-B binding site. In patients, prevalence genotypes 1A 1B, predominant Europe, observed. has been important understand whether specific scenario could affect latency, particular kidneys. Moreover, for more accurate PML risk stratification, testing seems useful identify who harbor but undetectable humoral immune response. it may rearrangement: particular, expression PBMCs play crucial role replication rearrangement.